HSBC Holdings
SRPT icon

HSBC Holdings’s Sarepta Therapeutics SRPT Stock Holding History

HSBC Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$12.1M – 3245
2024
Q4 		$12.1M Buy
+100,000
New +$12.3M 0.01% 871

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HSBC Holdings's SRPT Position: Q2 2026 in Review

HSBC Holdings increased its Sarepta Therapeutics (SRPT) stake by 26% in Q2 2026, buying an estimated $278K and bringing the position to 70,233 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

HSBC Holdings first reported a position in SRPT in Q4 2016 and has held it in 29 quarters since. The position peaked at $21.9M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • HSBC Holdings held 70,233 shares of Sarepta Therapeutics worth $1.27M as of Q2 2026.
  • HSBC Holdings bought 14,684 Sarepta Therapeutics shares in Q2 2026, an estimated $278K.
  • Sarepta Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1809 holding.
  • HSBC Holdings first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 29 quarters since.
  • HSBC Holdings's Sarepta Therapeutics position peaked at $21.9M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.